… that elafin has significant diagnostic and prognostic value as a biomarker of skin GVHD. …
We evaluated elafin as a biomarker of skin GVHD in a validation set of 492 allogeneic BMT …

… In contrast to the initial report of elafin as a biomarker of skin GVHD, the present study
found no difference in elafin concentration between clinical stages of skin disease and no …

… Elafin has been recognized as a potential biomarker that differentiates … We set the search
strategy incorporating the search terms, ‘Elafin’, ‘graft versus host disease’, and ‘GVHD’, and …

… skin and absent in normal epidermis. Recently plasma elafin has been recognized as a
biomarker of skin GVHD (as shown by significantly higher levels at the onset of skin GVHD) and …

… Although the latter confirmed our results, the use of biomarkers in routine clinical practice …
fact that elafin is a valid plasma biomarker in the setting of haplo-HSCT with PTCy. Elafin could …

… The skin is the most common organ involved in acute graft‐versus‐host disease (GvHD).
Because histopathology … Recently, elafin was identified as an important plasma biomarker for …

… We evaluated whether the analysis of elafin expression in skin would allow distinguishing
aGVHD … levels could be helpful diagnostic and predictive biomarkers in cutaneous aGVHD. …

… There are no plasma biomarkers that are specific to any … graft versus host disease (GVHD):
skin, GI tract and liver. We sought to identify a biomarker that is specific for GVHD of the skin …

… We showed that plasma elafin levels have significant diagnostic and prognostic power as
a biomarker of skin GVHD (2). Using the same proteomics strategy, we discovered …

… elafin has been the only known biomarker of cutaneous GvHD used for both serum and skin
… In our study, elafin staining did not prove useful in distinguishing aGvHD from SJS/TEN and …